Revalesio, a biomedical company headquartered in Tacoma, Wash., says it’s been cleared to benefit from federal incentives for the development of a drug that could help treat a neurodegenerative disease known as amyotrophic lateral sclerosis, or ALS.
ALS is known as Lou Gehrig’s disease, but today’s most famous patient is British physicist Stephen Hawking, who was diagnosed with the malady more than 50 years ago.
The disease affects 12,000 to 15,000 patients in the U.S., and an estimated 6,000 Americans are diagnosed with ALS every year.
